2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Checkpoint Inhibitor, Immunotherapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Practice Models, Value, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, CMML, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Survivorship, Study Population, Human, Adult
PAPER

3469 Dynamics of NRAS and KRAS mutation clearance after intensive or lower-intensity chemotherapy and impact on outcomes in Pts with newly diagnosed AML

Georgio Medawar, MD, Monika Kulasekaran, MD2, Gautam Borthakur, MD3, Wei Ying Jen, BM BCh, FRCPath4, Jayastu Senapati, MBBS, MD, DM5, Mahesh Swaminathan, MD6, Keyur P. Patel, MD7, Sanam Loghavi, MD8, Guillermo Montalban-Bravo, MD9, Nicholas Short, MD10, Alex Bataller, MD, PhD11, Ghayas C. Issa, MD12, Eitan Kugler, MD PhD13, Farhad Ravandi, MD14, Hagop Kantarjian, MD15, Courtney DiNardo, MD, MSCE16, Naval Daver, MD17, Guillermo Garcia-Manero, MD18, Tapan Kadia I, MD19
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background

RAS pathway mutations (NRAS/KRAS) occur in 15–20% of newly diagnosed acute myeloid leukemia (AML). Emerging data suggest RAS mutations drive resistance to venetoclax-based regimens via MCL-1-mediated apoptosis evasion. Whether or not clearance of RAS mutations after induction predicts survival, and whether this differs by regimen intensity, remains undefined. Using serial NGS-based testing we evaluated NRAS/KRAS clearance and outcomes across intensive chemotherapy (IC) and low-intensity chemotherapy (LIC) regimens, ± venetoclax (Ven).

Methods

We retrospectively reviewed patients (pts) with newly diagnosed (ND) AML from 2016-2025 with NRAS or KRAS mutations at diagnosis who had NGS testing at baseline and time of best response. NGS testing was performed using a targeted panel of myeloid-related genes with a sensitivity of ~2% variant allelic frequency for single nucleotide variants and multinucleotide variants. Pts were stratified by treatment intensity (IC±Ven vs LIC±Ven) and, within LIC, by regimen (HMA±Ven vs Clad/LDAC±Ven). Clearance was defined as undetectable mutation on post-induction marrow NGS at best response. Overall survival (OS) and relapse-free survival (RFS) were compared by clearance status and regimen using log-rank tests; clearance rates by Fisher's exact test.

Results

Among 418 ND-AML pts with NRAS and/or KRAS mutations, 236 (56%) achieved CR/CRi; 193 (82%) had post-induction NGS at best response and were analyzed (147 NRAS, 64 KRAS; 18 co-mutated). There were no CBF-AML cases.

Pts with NRAS-mutated (-mut) AML had median (med) age of 64 yrs (range, 21-85). ASXL1, DNMT3A, TET2 and NPM1 were present in 44 (30%), 53 (36%), 74 (50%) and 43 (29%) in cases, respectively. Pts required a med of 1 cycle (range 1–7) to best response. Overall, 107 (73%) cleared the mutation after a med of 1 cycle (1–3). Pts who had NRAS mutation clearance had a superior med OS (43.9 vs 13.2 months (m), p=0.0008) and RFS (27.5 vs 8.8 m, p=0.0003) compared to those with persistent NRAS mutation; transplant rates in the two groups were 42% vs 23% (p= 0.29), respectively. When analyzed by treatment intensity, pts who received IC±Ven (n=64; 38% ELN-2022 adverse risk) achieved clearance in 92% vs 58% with LIC±Ven (n=83; 7% ELN-2024 adverse risk) (p<0.0001). Within the IC group, pts who cleared NRAS had superior med RFS (NR vs 8.2 m, p=0.0032) and OS (NR vs 10.6 m, p=0.006). Within the LIC group, NRAS clearance trended toward better med RFS (14.1 vs 9 m, p=0.14) and OS (18.4 vs 14.7 m, p=0.19). Among pts treated with LIC, clearance was numerically higher with Clad/LDAC+Ven vs HMA+Ven (74% vs 54%, p=0.19); Med RFS/OS were significantly better with Clad/LDAC+Ven (24.6 vs 9.1 m [p=0.008], and 24.6 vs 15.1 m [p=0.03]).

Pts with KRAS-mut AML had a med age of 68 yrs (range 24-83). ASXL1, DNMT3A, TET2 and NPM1 were present in 22 (34%), 17 (27%), 32 (50%), and 14 (22%) of cases, respectively. Pts required a med of 1 cycle (1–4) to best response. Overall, 45 (70%) clear the KRAS mutation after a med 1 cycle (1–4). Clearance of KRAS was associated with a superior med RFS (12.4 vs 6.2 m, p=0.035) and a trend toward better OS (20.3 vs 14.3 m, p=0.067) compared with the lack of clearance; transplant rates were 31% vs 26% (p=0.8), respectively. When analyzed by treatment intensity, IC±Ven (n=26; 31% adverse risk) achieved clearance in 81% vs. 63% with LIC±Ven (n=38; 16% adverse risk) (p=0.17). Within the IC group, clearance of KRAS did not impact med RFS or OS (both NR vs NR; p=0.74, p=0.62). However, within the LIC group, clearance was associated with a significantly better med RFS (8.8 vs 3.6 m, p=0.04) and OS (18.7 vs 6 m, p=0.05). Among LIC regimens, clearance was similar with Clad/LDAC+Ven vs HMA+Ven (64% vs 55%, p=0.69); Med RFS/OS were similar with CLAD/LDAC+Ven vs HMA+Ven (7 vs 6 m [p=0.65] and 14.2 vs 7.9 m [p=0.83]).

Conclusions

NRAS/KRAS clearance after induction is associated with improved survival, though magnitude and significance differ by mutation and regimen intensity. IC achieves higher clearance rates for both mutations and confers a survival benefit for NRAS clearance, but not KRAS, where clearance-associated benefit was more pronounced with LIC regimens. The use of CLAD/LDAC+Ven as compared to HMA+Ven was associated with higher survival in NRAS-mut AML. Larger, prospective studies are needed, but these findings suggest RAS-subtype- and regimen-specific approaches to treatment selection and NGS monitoring may be warranted.

Georgio Medawar, MD: No relevant conflicts of interest to declare.